NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with Irish Pharmacist includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


ADVERTISMENT

ADVERTISMENT

Acute exercise has beneficial effects on the immune system during prostate cancer — study

By Irish Pharmacist - 28th Aug 2020

Lifestyles running, made in Barcelona.

New research published in Experimental Physiology has found that in prostate cancer survivors, a moderate bout of exercise kept the cell count of certain types of immune cells at a normal level, suggesting that exercise is safe for prostate cancer survivors. Twentyfour hours after a moderate bout of cycling, the immune cell count of natural killer (NK) cells, part of the body’s first line of defence, had returned to resting levels.

Prostate cancer treatments, including androgen deprivation therapy (ADT), have numerous adverse effects that reduce physical function and quality of life. Exercise is recommended for cancer survivors to reduce the side-effects of treatment and has shown to have many benefits.

However, the effects of prostate cancer treatment and acute exercise on the immune system have only been briefly examined. Exercise oncology guidelines were initially based on the responses seen in healthy, older adults. But individuals with cancer have different physiological responses to exercise, many of which we are only just beginning to understand.

Exercise helps the immune system mobilise by causing NK cells to move into the blood and be transported to areas of need, such as sites of infection or tumours. At the tissues, these cells move out of circulation and in cancer patients, they can infiltrate the tumour and potentially slow the tumour’s rate of growth.

This has been shown in animal models, but the exercise and immune response in cancer survivors is limited, with only a few studies in prostate cancer. The researchers, based at Victoria University in Australia, had volunteers (11 cancer survivors currently receiving ADT treatment, and 14 men with prostate cancer not on ADT, and eight healthy controls) complete a cycling task to determine their maximal aerobic fitness. The researchers chose to use a moderate-intensity exercise session that was consistent with current exercise oncology guidelines but was also a bout that would be practical for prostate cancer survivors to perform on their own.

To ensure that the exercise bout used to stimulate the immune system was the same degree of difficulty for everyone, they standardised based on their maximal effort. To determine immune function, they obtained blood samples before exercise, immediately after, and two hours after they finished cycling. The participants then came back 24 hours after exercise, and immune function was assessed again after one night of recovery. They also measured several key hormone levels, including adrenaline and noradrenaline, as they play a role in activating and mobilising the NK immune cells.

The researchers found that 24 hours after a moderate bout of cycling, the immune cell count of natural killer (NK) cells, part of the body’s first line of defence, had returned to resting levels. They also showed that the immune cell mobilisation with exercise does not appear to be significantly altered during prostate cancer treatment, which provides direct evidence that acute exercise that falls within current oncology guidelines also appears to be beneficial for the immune system.

One limitation of the study is the modest sample size, and also that they examined cytokines and proteins that are related to NK cell function but did not directly assess the killing capacity of the NK cells. Dr Erik D Hanson, first author on the study, said: “One of the most enjoyable aspects of working with these men is how willing these men are to help their fellow prostate cancer survivors. Many of them realise that these studies are not likely to benefit them directly.

However, they do not hesitate to volunteer and are willing to do just about whatever is asked of them
for the collective good.”

ADVERTISMENT

Latest

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

Latest Issue

Irish Pharmacist May 2024

Irish Pharmacist May 2024. Volume 25 | Issue 5 | May 2024. Read the latest issue of Irish Pharmacist here…

Read

OTC Update Spring 2024

Spring 2024 | Issue 1 | Volume 18. Read the latest issue of OTC Update here.

Read

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT